In Ontario, ovarian cancer causes 7% of female cancer deaths, exceeding cancer of the uterine cervix or corpus in women aged 50 years and over. For 1722 patients with ovarian cancer registered at the Ontario Cancer Foundation Clinics in 1938-1958, who received some or all of their treatment at the clinics or were untreated anywhere, the crude survival rate at five years was 28%. Survival was greatly influenced by extent of disease and by histological type; survival rates remained constant or rose slightly over successive periods although an increasing proportion of advanced cases were registered. The method of choice for initial treatment was panhysterectomy with bilateral salpingo-oophorectomy and radiotherapy. Agreement on classification by histological type and extent is urgently needed.
For the 827 patients with malignant testicular tumours registered at the Ontario Cancer Foundation's regional clinics in the period 1938-1961, the probability of surviving for five years after treatment was 59.8%; for the 731 patients who received all or part of their initial treatment at the clinics or were not treated anywhere, five-year survival probability was 62.7%. Most deaths from testicular cancer took place in the first two years after treatment, and 90% of recorded recurrences were diagnosed before the third anniversary. Survival rates were strongly influenced by histological type and extent of disease, and to some degree by age. Survival did not seem to be closely correlated with delay after first symptom, site or size of primary lesion, ectopia, surgical treatment of the abdominal nodes, site or dosage of radiation, or chemotherapy. The survival rates in this series of cases compare favourably with those of other large series.
In Ontario, leukemia causes about 4% of all cancer deaths, ranging from nearly 50% at under 5 years of age to 1-3% at age 50 and over. Age-specific death rates are highest among older people; at all ages, male deaths exceed female deaths. Only about 20% of all leukemia patients in Ontario are registered at Ontario Cancer Clinics; the proportion changed sharply with the advent of chemotherapy. For 1258 patients registered in 1938-1963, the crude one-year survival rate was 50%, ranging from 9% for acute leukemia to about 60% for non-acute lymphatic and myeloid leukemia. The long-term outlook was much better for non-acute lymphatic leukemia than for non-acute myeloid leukemia. For acute leukemia, the treatment of choice was chemotherapy; for non-acute lymphatic leukemia, radiotherapy was used, followed, if required, by chemotherapy or further radiotherapy. For non-acute myeloid leukemia, the advantage of chemotherapy over radiotherapy was not established.